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ABSTRACT 
 
Peroxisome proliferator-activated receptor gamma (PPARγ) belongs to a family of 
ligand-activated nuclear receptors and its ligands are known to control many 
physiological and pathological situations. Its role in the central nervous system has been 
under intense analysis during the last years. Here we show a novel function for PPARγ 
in controlling stem cell expansion in the adult mammalian brain. Adult rats treated with 
pioglitazone, a specific ligand of PPARγ, had elevated numbers of proliferating 
progenitor cells in the subventricular zone and the rostral migratory stream. Electron 
microscopy analysis also showed important changes in the subventricular zone 
ultrastructure of pioglitazone-treated animals including an increased number of 
migratory cell chains. These results were further confirmed in vitro. Neurosphere assays 
revealed significant increases in the number of neurosphere forming cells from 
pioglitazone- and rosiglitazone (two specific ligands of PPARγ receptor)-treated 
cultures that exhibited enhanced capacity for cell migration and differentiation. The 
effects of pioglitazone were blocked by the PPARγ receptor antagonists GW9662 and 
T0070907, suggesting that its effects are mediated by a mechanism dependent on 
PPARγ activation. These results indicate for the first time that activation of PPARγ 
receptor directly regulates proliferation, differentiation, and migration of neural stem 
cells in vivo.  
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INTRODUCTION 
 
The ability of the adult central nervous system to produce new neurons is limited, 
rendering the brain particularly vulnerable to injury and disease. In mammals, the 
majority of neurons are born by the prenatal period, but it is well established that 
neurons continue to arise in two niches of the adult brain, the subventricular zone (SVZ) 
of the lateral ventricle and the subgranular zone (SGZ) of the dentate gyrus (Gage et al. 
1998; Luskin et al. 1997). Progenitor cells in the SVZ migrate to the olfactory bulb 
(OB) through the rostral migratory stream (RMS) where they differentiate into granule 
and periglomerular neurons. In the hippocampus, new neurons arise in the subgranular 
zone of the dentate gyrus. Both cell-extrinsic and cell-intrinsic factors have been shown 
to influence the maintenance and regulation of the neurogenic system in vivo (Ostenfeld 
and Svendsen 2003). Among the extrinsic factors a number of growth factors have been 
shown to affect the proliferation and differentiation of precursor cell populations, 
including insulin-like growth factor-1 (Anderson et al. 2002), epidermal growth factor 
(EGF) (Doetsch et al. 2002), basic fibroblast growth factor (bFGF) (Bartlett et al. 1995; 
Johe et al. 1996), and other factors like the brain-derived neurotrophic factor (Larsen et 
al. 2007) and Noggin (Lim et al. 2000). Additionally, adult neurogenesis has also been 
shown to be influenced by the activation of several intrinsic transcription factors among 
which are the transcription factors Pax 6 (Hack et al. 2005; Kohwi et al. 2005), Notch 1 
(Lutolf et al. 2002), and Mash 1 (Parras et al. 2004). 
  
Peroxisome proliferator-activated receptor gamma (PPARγ) is a member of the nuclear 
receptor family of transcription factors, which includes different proteins mediating 
ligand-dependent transcriptional activation (Debril et al. 2001; Dreyer et al. 1992; 
Kliewer et al. 1994; Michalik et al. 2006). PPARγ participates in many biological 
processes including adipocyte differentiation, lipid and glucose homeostasis (Desvergne 
and Wahli 1999; Rosen and Spiegelman 2001; Tontonoz et al. 1994), and regulation of 
inflammatory responses (Ricote et al. 1999; Szeles et al. 2007). Several natural and 
synthetic ligands for PPARγ have been described. Among the natural ligands, 
polyunsaturated fatty acids and some prostaglandins and leukotrienes have been shown 
to be potent activators of this receptor (Forman et al. 1995; Jiang et al. 1998; Paruchuri 
et al. 2008). Synthetic ligands include the anti-diabetic thiazolidinediones (TZDs) such 
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as troglitazone, pioglitazone, and rosiglitazone (Blaschke et al. 2006; Desvergne and 
Wahli 1999; Rosen and Spiegelman 2001) as well as some new compounds, the aryl-
tyorosine derivatives, described as novel PPARγ ligands (Brown et al. 1999). 
 
Beyond these functions, recent data have shown that PPARγ acts as a regulator of 
central nervous system inflammation (Heneka et al. 2005) and is a powerful 
pharmacological target for counteracting neurodegeneration, as shown in animal models 
(e.g. of Parkinson’s and Alzheimer’s diseases) review in (Heneka and Landreth 2007). 
In this context, data from animal experiments strongly indicate that ligands of PPARγ 
confer neuroprotection and neurological improvement following brain injury 
(Abdelrahman et al. 2005; Bernardo et al. 2000; Landreth and Heneka 2001; Townsend 
and Pratico 2005) and PPARγ ligands, including the antidiabetic thiazolidinediones 
(TZDs), have been implicated in anti-inflammatory process in diverse tissues, including 
the brain (Kielian and Drew 2003; Ricote et al. 1999). Consistent with this idea, we 
have recently demonstrated that different members of the thiadiazolidinone (TDZD) 
family (chemical structure-related derivatives to TZDs) inhibited the activation of 
astrocytes and microglial cells in vitro and are potent anti-inflammatory and 
neuroprotective agents against kainic acid-induced in vivo excitotoxicity, through a 
mechanism apparently involving PPARγ activation (Luna-Medina et al. 2005; Luna-
Medina et al. 2007b). We found a significant preservation of hippocampal cells in 
TDZD-injected rats compared with abundant neuronal loss in CA1, CA3, and hilus after 
injection with kainic acid (Luna-Medina et al. 2007b), suggesting a possible neurogenic 
action of the TDZD compound. Also, we have preliminary data showing that the TDZD 
compound NP031112, a potent anti-inflammatory and neuroprotective agent, which is 
currently under Phase II clinical trial for the treatment of Alzheimer´s disease, is a 
powerful inducer of neurogenesis in the two neurogenic niches, subventricular zone and 
hippocampus, of adult rats (Luna-Medina et al. 2007a).   
  
On the basis of the previous evidence, in this study we were interested in determining 
whether activation of PPARγ might have a role in the proliferation, differentiation, and 
migration of neural progenitor cells. Our studies showed that pioglitazone, a specific 
ligand of PPARγ, is a potent inducer of neuroblasts formation and migration in the SVZ 
of adult rats.  In vitro, PPARγ ligands increased the number, differentiation and 
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migration capacity of adult rat neurospheres. Altogether, these findings suggest that 
ligands of PPARγ regulate neural progenitor cell proliferation and migration and may 
influence their differentiation in adult forebrain. 
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MATERIALS AND METHODS 
 
Animals. All animal related procedures were approved by the Laboratory Animal Care 
and Use Committee of the Consejo Superior de Investigaciones Científicas and were 
conducted in accordance with the guidelines of the European Communities Council, 
directive 86/609/EEC. All efforts were made to minimize animal suffering and to 
reduce the number of animals used. Adult (8-12 weeks old) Wistar rats were used 
throughout the study. 
 
Pioglitazone and bromodeoxyuridine administration. Adult male Wistar rats (n=5 
per group) housed in a 12-hour light-dark cycle animal facility received daily 
intragastrical administration of pioglitazone (20mg/kg body weight) for 3 consecutive 
days. This dose of pioglitazone was chosen because it has been shown to be effective in 
vivo in different previously published works (Breidert et al. 2002; Ji et al. 2009; Peiris et 
al. 2007; Saitoh et al. 2007; Schmerbach et al. 2008). In order to label the entire 
population of fast proliferating SVZ and RMS cells, rats were intraperitoneally injected 
with 5-bromo-2-deoxyuridine (BrdU, 50 mg/kg) 24 h or 21 days before sacrifice.  
 
Tissue preparation,histology and immunohistochemistry. After treatment, the 
animals were anaesthetized and perfused transcardially with 4% paraformaldehyde 
solution. The brains were removed, postfixed in the same solution at 4ºC overnight, 
cryoprotected in the paraformaldehyde solution containing 30% sucrose, frozen, and 30 
µm coronal and sagital sections were obtained in a cryostat. Free floating sections were 
processed for cresyl violet (Nissl stain) and immunohistochemistry using 
immunofluorescence analysis or diaminobenzidine method as previously described 
(Luna-Medina et al. 2007b). For BrdU detection, samples were first incubated with 2M 
HCl for 30 min at 37º before blocking 1 hour in PBS containing 5% normal serum, 
0.1M lysine and 0.1% Triton X-100. Sections were then incubated with anti-BrdU 
mouse monoclonal (DAKO, Denmark) and anti-neuN rabbit polyclonal (Chemicon) 
antibodies at 4ºC overnight, washed three times and incubated with AlexaFluor 488 and 
Alexa 647 secondary antibodies for 1h at room temperature. After rinses, sections were 
mounted with Vectashield. Images were obtained using a Radiance 2100 confocal 
microscope (Bio-Rad, Hercules, CA) with a 488 laser line to excite Alexa-488 and a 
647 laser line to excite Alexa-647. Confocal microscope settings were adjusted to 
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produce the optimum signal-to-noise ratio. BrdU-positive cells were scored throughout 
the entire SVZ and RMS. One section every 60µm was analyzed at high magnification 
(x 40). For the quantification of immunoreactive BrdU/NeuN cells in the olfactory bulb, 
the number of positive cells was counted in 5 independent random fields (x400 
magnification), in 5 different sagital sections per animal (n=5 animals). For 
doublecortin (DCX) and β-III-tubulin detection floating sections were immersed in 3% 
H2O2 to inactivate endogenous peroxidase, blocked for 2 h at room temperature in 5% 
normal horse serum in PBS, containing 4% bovine serum albumin, 0.1 M lysine and 
0.1% Triton X-100. Afterwards, the sections were incubated overnight with anti-
doublecortin goat (Santa Cruz, CA), anti-PSA-NCAM mouse (Chemicon), and anti- β-
III-tubulin mouse (Sigma) antibodies. After several rinses, sections were incubated for 1 
h with the corresponding biotinylated secondary antibody and then processed following 
the avidin-biotin protocol (ABC, Vectastain kit. Vector Labs). Tissues were then 
mounted onto gelatin-coated slides, dried, dehydrated in xylene, and mounted with 
DePeX (Serva, Heidelberg, Germany). The slides were examined with a Zeiss Axiophot 
microscope, equipped with an Olympus DP-50 digital camera, and a Leica MZ6 
modular stereomicroscope.   
 
Electron microscopy. Rats were deeply anesthetized and perfused transcardially with 
0.9% saline, followed by Karnovsky’s fixative (2% paraformaldehyde and 2.5% 
glutaraldehyde). Brains were postfixed overnight in the same fixative and washed in 0.1 
M phosphate buffer (PB). Coronal 200 µm sections were cut on a vibratome. Sections 
were then post-fixed in 2% osmium for 2 hours, rinsed, dehydrated and finally 
embedded in Araldite (Durcupan ACM, Fluka, Switzerland). Serial 1.5 µm semithin 
sections were cut with a diamond knife and stained with 1% toluidine blue to study the 
organization of the SVZ and RMS. In order to identify the different individual cell types 
in the SVZ, ultrathin (70 nm) sections were cut with a diamond knife. 
Photomicrographs were obtained under a Fei microscope (Tecnai-Spirit) using a digital 
camera (Morada, Soft-imaging System). 
 
Neurosphere cultures. Neurosphere (NS) cultures were derived from adult rats and 
induced to proliferate using established passaging methods to achieve optimal cellular 
expansion according to published protocols (Ferron et al. 2007). Briefly, rats were 
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decapitated, brains removed and the subventricular zone was dissected, minced and 
dissociated with DMEM (Invitrogen) containing glutamine, gentamicin and fungizone. 
After treatment with trypsin-EDTA, hialuronidase and DNAse, myelin was removed by 
using DPBS (Invitrogen). Cells were seeded into 6-well dishes and cultured in 
Dubecco’s Modified Eagle’s Medium (DMEM)/F12 (1:1, Invitrogen) containing 10 
ng/ml epidermal growth factor (EGF, Peprotech, London, UK), 10 ng/ml fibroblast 
growth factor (FGF, Peprotech) and N2 medium (Gibco). After 3 days in culture, some 
primary NS cultures were treated with pioglitazone (5, 10 and 30 µM, Takeda Europe 
R&D Centre Ltd., London, UK), rosiglitazone (5, 10 and 30 µM, Cayman, Ann Arbor, 
MI), or vehicle for another 7 days. Some cultures were pretreated for 30 min with 
GW9662 (10 and 30µM, Cayman) and T0070907 (25 and 50µM, Cayman). These 
primary neurospheres were then dissociated and replated in normal proliferative 
conditions for another 7-9 days to score the number of secondary neurospheres 
generated. Six to eight wells per condition tested were counted. 
 
Protein extraction and Western blot analysis. After sacrifice, brains were 
immediately dissected and cortex, hippocampus and cerebellum isolated and frozen on 
dry ice and stored at −80°C until protein extraction. For protein extraction, samples 
were homogenized in ice-cold RIPA buffer and equal quantities of total protein were 
separated by 10% SDS-PAGE. After electrophoresis, proteins were transferred to 
nitrocellulose membranes (Protran, Whatman, Dassel, Germany) and blots were probed 
with anti-PPARγ (Santa Cruz, Santa Cruz, CA) antibody. For each sample, the α-
tubulin level expression  (Sigma) was determined as a loading control. 
 
Growth and proliferation measurements. Primary and secondary NS cells were 
counted and their size was analyzed using the Nikon Digital Sight, SD-L1 (Nikon, 
Japan). Proliferation assays were carried out by culturing whole primary NS, in the 
presence or absence of the indicated stimuli, during 10 days. Afterwards they were 
plated onto poly-l-lysine coated coverslips for 24 h. Cells were then fixed in cold 
methanol, stained with anti-Ki67 antibody (Novo Castra Laboratories, Newcastle, UK) 
and processed for immunocytochemistry as previously described (Luna-Medina et al. 
2005). 
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Differentiation of NS cultures. In order to determine the ability of rosiglitazone and 
pioglitazone to produce neurons, astrocytes or oligodendrocytes, whole neurospheres 
from 10-day old cultures were plated onto poly-l-lysine coated coverslips in the absence 
of exogenous growth factors. Cells were allowed to adhere for 24 h and fixed using cold 
methanol. Cells were then processed for immunocytochemistry. 
 
Assay of cell migration. Single spheres were picked up with a pipette and plated onto 
poly-L-lysine coated 35 mm dishes. At 48 h post-plating, the outgrowth of the 
neurosphere cells was examined under the phase contrast microscope, and the images 
were acquired with a Nikon Digital Sight, SD-L1 software. The farthest distance of cell 
migration was calculated from the edge of the sphere. At least 10 plated neurospheres 
per situation were analyzed. 
  
Immunocytochemistry. Cells were processed for immunocytochemistry as previously 
described (Luna-Medina et al. 2005). Briefly, at the end of the treatment period, NS 
cultures were grown on glass cover-slips in 24-well cell culture plates. Cultures were 
then washed with phosphate-buffered-saline (PBS) and fixed for 30 minutes with 4% 
paraformaldehyde at 25°C, and permeabilized with 0.1% Triton X-100 for 30 minutes at 
37ºC. After 1 hour incubation with the corresponding primary antibody, cells were 
washed with phosphate-buffered-saline and incubated with an Alexa-labeled secondary 
antibody (Molecular Probes; Leiden, The Netherlands) for 45 minutes at 37°C. Later on, 
images were obtained using a Radiance 2100 confocal microscope (Bio-Rad, Hercules, 
CA) as described for immunohistochemistry. Quantification was undertaken using the 
image analySIS software (Soft Imaging System Corp., Münster, Germany) and 
normalized to total nuclei. Primary antibodies were directed against the following: 
MAP-2 (mouse; Sigma), GFAP (mouse; Sigma), active caspase-3 (rabbit, R&D) and 
CNPase (mouse, Chemicon, Temecula, CA). Dapi staining was used as a nuclear 
marker. For quantification of the number of cells producing a given marker, in any 
given experiment the number of positive cells leaving the neurosphere body were then 
counted. Cell numbers were estimated from a total of six to eight neurospheres per 
condition over three independent experiments.  
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Statistical determinations. Data are given as the mean ± SD. of at least five different 
animals per group. Comparisons of different groups were performed using the Student’s 
t test with p≤0.05 being considered significant. 
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RESULTS 
Since pioglitazone is a specific ligand of the nuclear receptor PPARγ, we first analyzed 
whether PPARγ was expressed in the adult brain, particularly in neurogenic areas. 
Western blot and immunohistochemistry (Supplementary Figure 1) analysis 
demonstrated that PPARγ was expressed throughout the central nervous system of the 
adult rat. Interestingly, significant levels of PPARγ protein were found in the two 
neurogenic niches, the SVZ and the hippocampus. PPARgamma expression was found 
in the SVZ as well as in the RMS. PPARγ is expressed at high levels in the RMS and 
remains detectable in these cells as they migrate into the OB.  
 
 
Effect of pioglitazone on proliferation of adult progenitor cells in vivo in the 
subventricular zone and rostral migratory stream.  
We first analyzed whether pioglitazone affected the proliferation kinetics of mitotically 
active progenitor cells in the SVZ and RMS. For this in vivo study we decided to use 
this PPARγ ligand because of its well known ability to cross the blood brain barrier. To 
this end, rats were treated during 3 days with pioglitazone or vehicle followed by one 
BrdU injection 24 h before sacrifice. Coronal sections were stained with cressyl violet 
(Nissl staining) or with specific anti-BrdU and anti-NeuN antibodies (Fig 1). Nissl 
staining showed an increase in the size of the SVZ in animals treated with pioglitazone 
(Fig. 1A, right panel), in comparison with controls. No morphological alterations were 
observed on the rest of the neuropil or in other cortical, septal or striatal structures. Also 
a widespread distribution of the RMS was observed in pioglitazone-treated animals 
(Fig. 1C, right panel). Twenty-four hours after the BrdU injection there was a 
considerable increase in the number of labeled cells both in the SVZ (Fig. 1B, right 
panel) and RMS (Fig. 1D, right panel) of pioglitazone-treated rats relative to the 
vehicle-treated control group SVZ (Fig 1B, left panel) and RMS (Fig 1D, left panel). 
Pioglitazone treatment increased SVZ BrdU-labeled cell numbers by about 35 % above 
control values (Fig. 1E). Similar results were obtained in the RMS where a significant 
increase in the number of BrdU cells was found in pioglitazone-treated animals in 
comparison with control ones (Fig. F). Besides a higher number of proliferating cells in 
the RMS, we also found that pioglitazone-treated animals showed a widespread RMS 
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(Fig 1D, right panel), compared to control rats, in which the RMS usually appeared as a 
dense cluster of cells (Fig 1D, left panel).  
 
In order to determine the cell types that were increased in the RMS and the SVZ, rats 
were treated during 3 days with pioglitazone or vehicle and sagittal or coronal brain 
sections were stained for DCX+. DCX is a microtubule-associated protein, which is a 
valuable endogenous marker for dividing neuroblasts and immature neurons (Brown et 
al. 2003; Couillard-Despres et al. 2005). As shown in Figure 2A-B, pioglitazone 
treatment clearly increases the number of DCX+ cells in the RMS (Fig. 2A), specially in 
some areas, such as the anterior arm or the elbow (Fig. 2A, right panel). Similar results 
were observed in the SVZ of pioglitazone-treated animals (Fig. 2B, right panel) with an 
increase in the migrating chain of cells. The pioglitazone-induced increase in the 
number of neuroblast was further substantiated by staining with PSA-NCAM, a marker 
of migrating neuroblasts (Fig. 2C). As happened with the number of DCX+ cells, 
animals treated with pioglitazone presented a higher number of PSA-NCAM-stained 
cells in the RMS. To characterize the cells marked in the SVZ, coronal sections were 
stained with an specific anti-β tubulin antibody, a molecule present in the migrating 
neuronal precursors (Doetsch and Alvarez-Buylla 1996). Our results clearly showed an 
increase in β-tubulin staining in the pioglitazone-treated animals (Fig. 2D, right panel). 
 
Effect of pioglitazone on migrating cells and the subventricular zone.  
We then analyzed the morphological features of the SVZ in the different groups of 
animals. To this end, we performed light and electron microscopy (EM) analysis on 
coronal sections of the ventricular lateral wall of the SVZ. EM allows characterization 
and identification of SZV cell types through their specific ultrastructural features, which 
have been well established in rodents (Danilov et al. 2009; Doetsch et al. 1997).  
Analizing toluidine blue-stained semithin sections of the SVZ of control animals, next 
to the ependymal lining we found chains of neuroblasts (Fig 3A). However, 
pioglitazone-treated animals (Fig 3B) displayed an expanded SVZ, with an increased 
number of migrating neuroblasts. These cell clusters were located deeply in the 
neuropil.  
 
EM analysis showed a typical SVZ structure in control animals (Fig 3C). Close to the 
ependymal cell lining, we found chains (Fig. 3C, pointed line) of migrating cells (type 
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A). These cells were identified by their small size and dark scanty cytoplasm. 
Astrocytes or type B cells were identified as large, less electrodense cells, rich of 
intermediate filaments. After pioglitazone treatment, the SVZ showed several 
ultrastructural changes. First, an increased number of neuroblasts were observed. These 
neuroblasts, in comparison with control animals, showed an irregular shape (Fig 3D). 
Moreover, migrating cell chains were located deeper in the SVZ compared to control 
rats. Additionally, intercellular spaces characteristic of migrating neuroblasts were more 
prominent in the pioglitazone-treated animals (Fig.3F), compared with controls (Fig 3 
E). Signs of pathological events or tumoral cells were also absent. Regarding the RMS, 
migrating type A cells and astrocytes were observed in control animals; these cells 
accumulated forming a typical dense cell mass (Fig 3 G). The RMS of pioglitazone-
treated animals (Fig 3 H) showed dispersed chains of migrating neuroblasts, which 
tended to spread invading a larger surface. 
 
Effect of pioglitazone on newly generated cells in the olfactory bulb.  
The neuronal differentiation of newborn cells in the olfactory bulb was assessed using 
double immunofluorescence labelling for BrdU and NeuN (postmitotic and 
postmigrational neurons), 21 days after treatment with pioglitazone and BrdU injection 
(Fig. 4). At this time most of BrdU-positive cells have reached the granule cell layer via 
the RMS, and express a neuronal phenotype (Winner et al. 2002). The number of 
BrdU/NeuN-positive cells in the granule cell layer was quantified as described in 
Material and Methods. Our results showed that after 21 days, there is a significant 
increase in the amount of newly generated neurons (BrdU/NeuN immunoreactive cells) 
in this area, in the animals treated with pioglitazone (Fig. 4A-B). That means that 
pioglitazone increases the number of new neurons into the olfactory bulb. 
 
The PPARγ ligands pioglitazone and rosiglitazone control the growth and survival 
of neurospheres.  
As a step toward understanding the role of PPARγ ligands on neurogenesis, we used 
primary and secondary derived neural stem cells as a model system. These studies allow 
us to better understand the mechanism by which pioglitazone acts as a neurogenic agent 
and the possible involvement of the nuclear receptor PPARγ. Primary neurospheres 
were obtained from adult rats and maintained and expanded as described in Materials 
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and Methods. We first analyzed by Western blotting whether PPARγ was expressed in 
the neurosphere cultures. As shown in Fig 5A, PPARγ was notably expressed in NS, 
regardless of their differentiation state. Next, we investigated whether addition of 
pioglitazone and rosiglitazone, another well-known and potent PPARγ ligand, to the 
medium of growing NS would increase their rate of formation and/or their size. To that 
point, different concentrations of pioglitazone and rosiglitazone on primary NS were 
used (Fig. 5C). 
 
After 10 days of growth in suspension, there was a significant increase in both the 
number and diameter of primary NS growing in the presence of both ligands (Fig. 5B, 
5C). Consistent with a role in stem cell regulation suggested by the in vivo experiments, 
pioglitazone- and rosiglitazone-treated NS exhibited an enhanced self-renewal capacity. 
Primary spheres derived from pioglitazone- and rosiglitazone-treated progenitors 
formed “secondary” NS when dissociated and replated (Fig. 5C), indicating self-
renewal capacity. Specifically, neonatal pioglitazone- and rosiglitazone-treated primary 
NS produced respectively 341 ± 15.7 and 336 ± 12.2 secondary NS, while non-treated 
neurospheres only produced 210 ± 10.5 secondary neurospheres. Treatment of 
neurosphere cultures with pioglitazone or rosiglitazone did not alter cell viability, as 
measured by active caspase-3 staining (Supplementary Figure 2). 
  
Next, we tested the possible implication of the PPARγ receptor in the observed effect of 
pioglitazone and rosiglitazone. To this end we analyzed whether the specific PPARγ 
antagonists GW9662 and T0070907 impaired the action of the drugs. As shown in Fig. 
5B and 5C, treatment of primary NS with these antagonists significantly inhibited the 
effects of the drugs on primary NS formation and size. Similar results were obtained on 
secondary NS pre-treated with GW (Fig. 5C, lower panel). These results suggest that 
both rosiglitazone and pioglitazone are acting through a PPARγ-dependent mechanism. 
  
These studies thus far demonstrate that PPARγ is expressed by NS and that their 
specific ligands pioglitazone and rosiglitazone enhance the number as well as the size of 
the NS generated from neonatal SVZ, suggesting that PPARγ activation by these factors 
regulates the proliferation of sphere forming progenitors. Therefore, proliferation of 
pioglitazone- and rosiglitazone-treated cells was assessed 7 days after treatment by 
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staining for Ki67, a marker of dividing cells. As expected, treatment of adherent 
primary NSC significantly increased Ki67-staining, indicating a direct effect of 
pioglitazone on proliferation (Fig. 5D). 
 
The PPARγ ligands pioglitazone and rosiglitazone alter migration patterns from 
neurospheres.  
In order to test whether pioglitazone and rosiglitazone modulate migration of NS, we 
exposed NS to both agents during 48 h. The results summarized in Fig. 6 indicate that 
migration in the presence of both, pioglitazone and rosiglitazone for 48 h resulted in an 
increased migration (1.6- and 1.5-fold, respectively of the controls). These cells moved 
long distances from the centre of the NS to often create overlapping zones of migration 
between adjacent NS. The cells from control NS remained close to the neurosphere 
origin and were observed in closely associated groups.  
 
 Next, we investigated whether PPARγ activation is involved in the effects upon 
migration of both pioglitazone and rosiglitazone. To this end, NS cultures were 
pretreated with the selective PPARγ antagonist GW9662 before exposure to these 
agents. As shown in Fig. 6, GW9662 suppressed the enhanced migration detected in 
pioglitazone- and rosiglitazone-treated NS cultures. These results suggest again an 
involvement of the nuclear receptor PPARγ in the migration effects of both compounds. 
 Altogether these data implicate the PPARγ receptor as a regulator of neuroblast 
formation and migration in the adult rat brain. 
 
The PPARγ ligands pioglitazone and rosiglitazone enhance differentiation of 
neurospheres after adhesion.  
To investigate whether PPARγ ligands influence cell differentiation after adhesion of 
NS, we analyzed by immunocytochemistry the different central nervous system cell 
types in the inside and the outgrowth of control, pioglitazone- and rosiglitazone-treated 
NS. Twenty-four hours after plating in the absence of EGF and FGF, NS extended 
multiple processes, which stained for the uncommitted neural precursor marker nestin. 
To identify the cell types generated by the effect of pioglitazone and rosiglitazone, cells 
were stained for immunofluorescence using antibodies against MAP-2 for neurons, 
GFAP for astrocytes, and CNPase for immature oligodendrocytes. As shown in Fig 7A 
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and 7B, in control cultures only scattered cells stained with GFAP or MAP-2 were 
observed. After treatment with PPARγ ligands the number of MAP-2- and GFAP-
positive cells was significantly increased specially in the outgrowth of the NS (Fig. 7). 
An increase of the length of GFAP immunoreactive fibers was observed, with long 
processes extended from the NS (high magnification in figure 7A). Figure 7B also 
shows in detail an increase of the number of migrating MAP-2 positive cells outside the 
NS. On the other hand, the number of CNPase positive oligodendrocytes precursors was 
not significantly altered by either rosiglitazone or pioglitazone (data not shown). 
Addition of GW9662 completely abolished the effects of both compounds on 
differentiation.  
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DISCUSSION 
 
Although its functional effect on brain damage has been recently investigated, there is 
almost no information about the effect that PPARγ activation has on neurogenesis in the 
adult brain. In the present study we used the TZD compound pioglitazone to 
demonstrate that PPARγ activation promotes proliferation, differentiation and migration 
of neuroblasts in the SVZ and RMS of adult rats. The results of this study demonstrate 
that PPARγ plays a role in regulating the expansion and differentiation of the stem cell 
population. This is evident in vitro by enhanced numbers of primary neurospheres and 
by rosiglitazone- and pioglitazone-mediated induction of GFAP+ and MAP2+ cells, and 
in vivo by an increased proliferation and a larger population of neuroblasts that finally 
integrate into the olfactory bulb as newly generated neurons. Enhancement of neural 
stem cells proliferation and differentiation by pioglitazone and rosiglitazone is possibly 
provoked by an activation of PPARγ, as demonstrated by the inhibition of their effects 
by the PPARγ antagonists GW9662 and T0070907. These studies reveal a novel role for 
PPARγ and may represent a potential therapeutic strategy for stem cell activation. 
  
Neurogenesis can be regulated at multiple points, such as proliferation, differentiation, 
and migration, processes that are controlled by a number of extracellular signalling cues 
(Alvarez-Buylla and Lim 2004; Lie et al. 2004). The SVZ harbors the largest pool of 
proliferating cells in adult mammals (Lois and Alvarez-Buylla 1993; Morshead et al. 
1994). Pioglitazone-treatment increased cell proliferation in the SVZ and the RMS, as 
indicated by the changes in the number of BrdU-labeled cells after 3 days of 
pioglitazone treatment. We also present evidence that PPARγ activation induces 
expansion of highly migratory SVZ progenitors in the adult rat. The increased 
proliferation, neuroblast migration in the SVZ and RMS, and subsequent increase of 
newborn neurons incorporated within the OB can be relevant in olfactory-associated 
behavior. There is evidence that adult mice short term memory is dependent of 
neurogenesis. Mice housed in an odor-enriched environment showed an increased 
survival of progenitor cells in the OB as well as an enhanced olfactory short memory 
(Rochefort et al. 2002). On the other hand, chemical inhibition of neurogenesis with the 
antimitotic drug araC, drastically reduced short-term olfactory memory (Breton-
Provencher et al. 2009). More recently, also long-term olfactory memory has been 
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shown to be dependent of neurogenesis. Both neurogenesis and long term memory are 
impaired after treatment with anti-mitotic drugs and protein synthesis inhibitors 
(Kermen et al. 2010 ; Sultan et al. 2010). Irradiation-induced decrease in constitutive 
neurogenesis in the OB has been shown to decrease olfactory long-term memory but not 
other olfactory functions (Lazarini et al. 2009). Also, Mak and Weiss (Mak and Weiss. 
2010) have shown that paternal-adult offspring recognition depends of OB neurogenesis 
and implicates prolactin signaling pathway (Mak and Weiss. 2010). Finally, it has been 
shown that chronic systemic inhibition of nitrite production increases proliferation in 
the subventricular zone and neurogenesis in the OB associated with a better olfactory 
learning performance (Romero-Grimaldi et al. 2006). Based on these data, together with 
our results, we could infer that pioglitazone -induced OB neurogenesis may improve 
olfactory-associated memory. 
 
We observed large chains of neuroblasts far away from the SVZ, deep in the striatum. 
This effect reminds to that observed when mice where administered EGF with an 
intraventricular osmotic pump (Doetsch et al. 2002). Speaking of stimulating 
neurogenesis, the advantage of pioglitazone is that it can be administered 
intragastrically for a systemic effect. To our knowledge, this paper is the first direct 
demonstration of an involvement of PPARγ in the proliferation, migration, and 
differentiation of neural progenitor cells. Regarding the possible mechanism of action 
through which PPARγ regulates neural stem cell proliferation and differentiation, since 
this receptor is a transcription factor we favor the idea that this regulation takes place 
through direct activation of some genes involved in these processes (Mu et al. 2010). 
  
The data obtained here also show that activation of PPARγ also stimulates neural 
progenitor cell proliferation in neurospheres in vitro. Our results suggest that PPARγ 
may regulate neural stem cell number by regulating the type of cell division. The 
formation of secondary neurospheres from primary neurospheres is indicative of self-
renewing stem cell division (Reynolds and Weiss 1996). The higher number of 
secondary neurospheres in pioglitazone- and rosiglitazone-treated NS cultures, indicate 
that the neural stem cells generated in presence of these factors underwent a higher 
proportion of self-renewing or symmetric cell divisions, leading to an expansion of the 
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stem cell pool. This lends support to the view that PPARγ activation might stimulate the 
capability to maintain stemness. 
  
Neural stem cells differentiate into neurons, astrocytes and oligodendrocytes (Gage 
2000; Temple 2001). Here, we show that PPARγ is involved in the control of neural 
stem cell differentiation. Our results indicate that activation of PPARγ causes neural 
stem cells to differentiate into astrocytes and neurons. The finding that rosiglitazone and 
pioglitazone are able to induce differentiation of NS cells differs from a previous report 
indicating that rosiglitazone induced proliferation of embryonic mouse NS cells and 
concurrently inhibited their differentiation into neurons (Wada et al. 2006b). This 
discrepancy may simply reflect methodological differences in isolating neural stem cells 
or different experimental conditions. Additionally, our work was performed with 
neurospheres isolated from the SVZ of adult rats, whereas the neurospheres by Wada et 
al. came from whole brain of mice embryos on days 13-14 of gestation, where other 
factors might be involved.  
  
Our work shows that PPARγ activation has a dual function in neural stem cells 
proliferation and differentiation, and suggests that ligands of PPARγ are not only 
mitogens for neural stem cells, but are also inducers of neuronal differentiation. It seems 
interesting that activation of PPARγ can promote both proliferation and differentiation. 
However, precedents for this phenomenon are seen in the case of insulin-like growth 
factor 1 (Arsenijevic and Weiss 1998) and leukotriene B4 (Wada et al. 2006a).  In this 
respect, we suggest that PPARγ can present a new strategy for restoring neurogenesis.  
  
Cell division in the SVZ is responsible for new neurons being added to the granular and 
the periglomerular layers of the olfactory bulb. These cells migrate through the RMS, 
where the majority disperses throughout the granule layer and a small percentage 
develops into interneurons in the periglomerular layer (Altman 1969; Doetsch et al. 
1997; Lois and Alvarez-Buylla 1994). The identification of factors that promote neural 
stem cell division and regulate proliferation, differentiation, and migration of their 
progeny would facilitate attempts to manipulate the production of new neurons and glia 
and help in understanding the ongoing maintenance of neural circuitry in the mature 
central nervous system. Here, we demonstrate an increased capacity of migration of 
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neurosphere-derived cells in response to both pioglitazone and rosiglitazone. This is 
especially important in a clinical setting since the identification of factors that not only 
promote neural stem cells proliferation and differentiation but also have a significant 
effect on their migration capacity might have an important regulatory role in SVZ 
migratory events in a brain injury context. One important finding in this study is that 
activation of PPARγ is required for the observed effects of rosiglitazone and 
pioglitazone. These results lend support to the view that activation of this receptor can 
have an important regulatory role in neurogenesis in the normal brain as well as after a 
brain injury or a neurodegenerative disease. In contrast with this, very recently Lee et al 
have shown that oral administration of rosiglitazone decreases neurogenesis in the 
mouse hippocampus (Lee et al.). The reasons for this discrepancy are uncertain, 
although it could be due to an indirect effect of the long treatment with rosiglitazone 
since it is well established that this drug, in contrast with pioglitazone, does not cross 
the blood brain barrier (Brodbeck et al. 2008; Landreth et al. 2008; Pedersen et al. 2006; 
Risner et al. 2006; Watson et al. 2005). 
 
In summary these studies clearly demonstrate that ligands of PPARγ play a versatile 
role, both in maintaining the progenitor pools and in inducing differentiation and 
migration of various cell types in the central nervous system through activation of this 
receptor. 
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FIGURE LEGENDS 
 
Fig. 1. Pioglitazone action on proliferating cells in the subventricular zone (SVZ) 
and the rostral migratory stream (RMS). Representative coronal sections showing 
Nissl staining and micrographs of BrdU-labeled cells (green) and NeuN-stained cells 
(red) in the SVZ (A, B) and in the RMS (C, D). Insets show higher magnifications of 
representative areas in the SVZ. (E, F) Quantification of BrdU-positive cells from the 
SVZ and RMS. Values are the mean ± sd from five different animals. *, P ≤ 0.05. Scale 
bar in B, D: 200 µm; insets: 100 µm. 
 
Fig. 2. Effect of PPARγ ligands on neural progenitor cells and their migration in 
the SVZ and RMS. Representative immunohistochemical images of DCX expression 
on sagital sections of RMS (A) and coronal sections of SVZ (B) of control and 
pioglitazone-treated animals. Insets show higher magnifications of the elbow area of 
RMS (A) and the SVZ (B). (C) Representative immunohistochemical images of PSA-
NCAM expression on sagital sections of control and pioglitazone-treated animals. Insets 
show higher magnifications of the elbow area of the RMS (D) Representative Coronal 
sections showing staining of the SVZ with an specific anti-β tubulin antibody. Scale bar 
in A, B, C, D: 250 µm, Insets: 25µm. 
  
Fig. 3. Effect of PPARγ ligands on migrating cells in the subventricular zone and 
the rostral migratory stream. (A) Toluidine blue-stained semithin section of the SVZ 
of a control rat, with dark round cells forming groups. (B) The SVZ of pioglitazone-
treated rats displayed an increased number of migrating neuroblasts clusters. (C) 
Ultrastructure of the SVZ of an untreated rat. Close to the ependymal cell lining, chains 
of migrating type A cells (pointed line) showed a dark scanty cytoplasm. Astrocytes 
(type B cells) were large and less electron-dense and contained abundant intermediate 
filaments. (D) After pioglitazone treatment, the number of neuroblasts increased and 
they showed an irregular shape. Migrating cell chains (pointed line) were deeper located 
in the SVZ compared to control rats. (E) Migrating neuroblasts typically displayed 
intercellular spaces (arrows), indicative of cell movement, in untreated rats. (F) In 
pioglitazone-treated mice, intercellular spaces were more prominent than in control 
animals (arrows). (G) Rostral migratory stream of a control animal. Migrating cells and 
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astrocytes accumulate forming a dense cell mass. (H) The rostral migratory stream of 
pioglitazone-treated mice showed a larger size, with an increased cell number. Scale bar 
in (A-B) 20 µm; (C-D) 10 µm; (E-F) 2 µm; (G-H) 50 µm. 
  
Fig.4. Effect of PPARγ ligands on newly generated neurons in the olfactory bulb. 
(A) Sagital sections showing the granule cell layer (GCL) of the olfactory bulb stained 
with BrdU (green) and NeuN (red). (B) Quantification of the number of BrdU/NeuN 
double stained cells into the GCL. Values are the mean ± sd from five different animals. 
***, P ≤ 0.001. Scale bar in (A) 100 µm; insets: 20 µm. 
 
Fig. 5. Effect of PPARγ ligands on neurosphere formation and growth. (A) Western 
blot analysis showing expression of PPARγ in neurospheres grown for 7 days 
(undifferentiated) or after an additional 2 days of adhesion (differentiated cultures). (B) 
Representative phase-contrast micrographs showing the size of neurospheres cultures 
for 7 days in the presence or absence of pioglitazone (10 µM) or rosiglitazone (30 µM). 
Some cultures were pre-incubated 1 hour with 30 µM GW9662 (GW) or 50 µM 
T0070907 prior to the addition of the compounds. Scale bars, 50 µm. (C) Effect of 
different doses of pioglitazone and rosiglitazone (5, 10 and 30 µM) on the growth of 
primary neurospheres. The number of neurospheres was counted and its diameter 
measured. The diameter of 50 primary and secondary neurospheres and the total number 
of neurospheres was determined in control and in pioglitazone- or rosiglitazone- treated 
cells. Some cultures were preincubated with GW9662 (GW, 30 µM) or with T0070907 
(T, 50 µM). The graphs in (C) demonstrate a significant increase in the number and 
diameter of the neurospheres in those cultures treated with pioglitazone or rosiglitazone. 
(D) Representative confocal images of Ki67 immunoreactivity (green) in primary 
neurospheres. Dapi staining (blue) was used as a nuclear marker. Quantification of 
Ki67+ cells reveals a significant induction of the Ki67+ cells in pioglitazone- and 
rosiglitazone-treated neurospheres. Results are mean values ± SD from three 
independent experiments performed in triplicate. **, P ≤ 0.01. 
  
Fig. 6.  Effect of PPARγ ligands on cell migration out of the neurosphere. Single 
neurospheres were plated on a poly-lysine-coated culture Petri dish in the presence or 
absence of pioglitazone (10 µM) or rosiglitazone (30 µM), and the cell migration out of 
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the sphere was monitored 48 h later. Some cultures were pre-incubated 1 hour with 30 
µM GW9662 (GW) prior to the addition of the compounds. (A) Shown are 
representative photomicrographs of three independent experiments. Scale bars, 25 µm. 
Insets show higher magnifications of the migrating area. Scale bars, 10 µM (B) 
Quantitative data of farthest distance of neural progenitor cell migration. **P≤ 0.01, 
versus control non-treated cultures. 
  
Fig. 7. Effect of PPARγ ligands on neurosphere differentiation. The neurospheres 
were grown for 7 days in the presence or absence of pioglitazone (10 µM) or 
rosiglitazone (30 µM) and then adhered for 2 days to allow differentiation. Cultures 
were labeled with MAP-2 (red, for neuronal cells), or GFAP (red, for astrocytes) 
antibodies and counterstained with DAPI (blue). Some cultures were pre-incubated 1 
hour with 30 µM GW9662 (GW) prior to the addition of pioglitazone. Addition of 
pioglitazone enhanced the number of GFAP (A) and MAP2 (B) positive cells inside the 
neurosphere. High magnification pictures in A and B show in detail some of the GFAP- 
or MAP-2-immunoreactive cells migrated from the neurosphere in culture.  
Representative confocal images of at least five independent experiments are shown. 
Scale bars, 10 µm. *, P ≤ 0.05; ***, P ≤ 0.001. 
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Figure S1. Expression of PPARγ in adult rat brain. (A): Western blot analysis 
showing expression of PPARγ in different regions of the brain. (B): 
Immunohistochemical analysis of brain sections showing expression of PPARγ in 
different cerebral areas. Among other areas, expression of PPARγ was detected in the 
subgranular zone (SVG) of the hippocampus, the rostral migratory stream (RMS) and in 
the subventricular zone (SVZ). Cb, cerebellum; Cx, cortex; Hip, hippocampus. Scale 
bars, 250 µm. Insets 25 µm. 
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Figure S2. Effect of pioglitazone or rosiglitazone on neurosphere´s viability. 
Treatment of neurosphere cultures with pioglitazone or rosiglitazone at different 
concentrations did not alter cell viability, as measured by active caspase-3 staining 
(green staining). DAPI staining is shown in blue. Scale bar, 100 µm. 
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